CAN (ON): Canadian firm enters German market through strategic partnership

MediPharm Labs has signed its first private label sales agreement for export to Europe, with ADREXpharma® GmbH, a licensed wholesale distributor of controlled drugs and medical cannabis which can serve all of the approximate 20,000 pharmacies across Germany. "Through its private label solutions platform, MediPharm Labs will supply ADREXpharma with high quality, purity assured, cannabis concentrate derivative products, including THC and CBD oil, for sale and distribution under the ADREXpharma brand in Germany upon receipt of applicable regulatory approvals," the team with the company explains.

“Germany is one of the largest and fastest-growing medical cannabis markets in the world and represents MediPharm Labs’ second major international milestone as we prepare to export our private label cannabis concentrates into Germany,” said Pat McCutcheon, CEO of MediPharm Labs. 

“MediPharm Labs shares our patient-centric focus and is an ideal partner for us to serve German patients in need,” said Mario Eimuth, Chief Executive Officer, ADREXpharma. “We are thrilled to partner with MediPharm Labs to extend our product range within the medicinal cannabis market with the highest pharmaceutical quality and to bring MediPharm Labs’ expertise in the cannabis extraction business to Germany.”

For more information:
MediPharm Labs
151 John Street, Barrie
+1 705 719 7425 
medipharmlabs.com 


Publication date:



Receive the daily newsletter in your email for free | Click here


Other news in this sector:


Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber